

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
14 February 2002 (14.02.2002)

PCT

(10) International Publication Number
WO 02/12233 A1

(51) International Patent Classification⁷: C07D 417/12, A61K 31/44, A61P 3/08

(74) Agent: RUTTER, Keith; SmithKline Beecham, Corporate Intellectual Property, Two New Horizons Court, Brentford, Middlesex TW8 9EP (GB).

(21) International Application Number: PCT/GB01/03514

(22) International Filing Date: 3 August 2001 (03.08.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0019226.0 4 August 2000 (04.08.2000) GB

(71) Applicant (for all designated States except US):
SMITHKLINE BEECHAM PLC [GB/GB]; New Horizons Court, Brentford, Middlesex TW8 9EP (GB).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(72) Inventors; and

(75) Inventors/Applicants (for US only): CRAIG, Andrew, Simon [GB/GB]; GlaxoSmithKline Pharmaceuticals, Old Powder Mills, Near Leigh, Tonbridge, Kent TN11 9AN (GB). HO, Tim, Chien, Ting [GB/GB]; GlaxoSmithKline Pharmaceuticals, Old Powder Mills, Near Leigh, Tonbridge, Kent TN11 9AN (GB). MILLAN, Michael [GB/GB]; GlaxoSmithKline Pharmaceuticals, Old Powder Mills, Near Leigh, Tonbridge, Kent TN11 9AN (GB).



WO 02/12233 A1

(54) Title: TARTRATE SALTS OF THIAZOLIDINEDIONE DERIVATIVE

(57) Abstract: A novel pharmaceutical compound 5-[4-2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione Meso- Tartrate or a solvate thereof, a process for preparing such a compound, a pharmaceutical composition comprising such a compound and the use of such a compound in medicine.

TARTRATE SALTS OF THIAZOLIDINEDIONE DERIVATIVE

This invention relates to a novel pharmaceutical, to a process for the preparation of the pharmaceutical and to the use of the pharmaceutical in medicine.

European Patent Application, Publication Number 0,306,228 relates to certain thiazolidinedione derivatives disclosed as having hypoglycaemic and hypolipidaemic activity. The compound of example 30 of EP 0,306,228 is 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (hereinafter also referred to as "Compound (I)").

International Patent Application, Publication Number WO94/05659 discloses certain salts of the compounds of EP 0,306,228 one of which is the tartrate salt. The preferred salt of WO94/05659 is the maleic acid salt.

It has now been discovered that Compound (I) forms a novel tartrate salt (hereinafter also referred to as the "Meso-Tartrate").

The novel Meso-Tartrate is a stable, high melting crystalline material hence is suitable for bulk preparation and handling. The Meso-Tartrate is amenable to large scale pharmaceutical processing, especially in manufacturing processes which require or generate heat, for example milling, fluid bed drying, spray drying, hot melt processing and sterilisation by autoclaving. The Meso-Tartrate can also be prepared by an efficient, economic and reproducible process particularly suited to large-scale preparation.

The novel Meso-Tartrate also has useful pharmaceutical properties and in particular it is indicated to be useful for the treatment and/or prophylaxis of diabetes mellitus, conditions associated with diabetes mellitus and certain complications thereof.

Accordingly, the present invention provides 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, meso-tartrate salt or a solvate thereof.

Suitably, the Meso-Tartrate is a mono-tartrate salt.

Mono tartrate salts also optionally comprise another monovalent salting ion such as an alkali metal or ammonium cation.

In one favoured aspect, the Meso-Tartrate provides an infrared spectrum substantially in accordance with Figure 1.

In one favoured aspect, the Meso-Tartrate provides a Raman spectrum substantially in accordance with Figure 2.

In one favoured aspect, the Meso-Tartrate provides an X-Ray powder diffraction pattern (XRPD) substantially in accordance with Table 1 or Figure 3.

In one favoured aspect, the Meso-Tartrate provides a Solid State ¹³C NMR spectrum substantially in accordance with Figure 4.

In one favoured aspect, the Meso-Tartrate provides a melting point in the range of from 147 to 157°C, such as 148 to 155 °C, for example 148 °C, 153 °C and 155 °C.

In a preferred aspect, the invention provides 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, meso-tartrate salt, characterised in that it provides:

- (i) an infrared spectrum substantially in accordance with Figure 1; and
- (ii) a Raman spectrum substantially in accordance with Figure 2; and
- (iii) an X-Ray powder diffraction pattern (XRPD) substantially in accordance with Table 1 or Figure 3; and
- (iv) a Solid State ¹³C NMR spectrum substantially in accordance with Figure 4.

The present invention encompasses the Meso-Tartrate or solvate thereof isolated in pure form or when admixed with other materials. Thus in one aspect there is provided the Meso-Tartrate or solvate thereof in isolated form.

In a further aspect there is provided the Meso-Tartrate or solvate thereof in a purified form.

In yet a further aspect there is provided the Meso-Tartrate or solvate thereof in crystalline form.

Also, the invention provides the Meso-Tartrate or solvate thereof in a solid pharmaceutically acceptable form, such as a solid dosage form, especially when adapted for oral administration.

Moreover, the invention also provides the Meso-Tartrate or solvate thereof in a pharmaceutically acceptable form, especially in bulk form, such form being particularly capable of pharmaceutical processing, especially in manufacturing processes which require or generate heat, for example milling; for example heat-drying especially fluid-bed drying or a spray drying; for example hot melt processing; for example heat-sterilisation such as autoclaving.

Furthermore, the invention provides the Meso-Tartrate or solvate thereof in a pharmaceutically acceptable form, especially in bulk form, and especially in form having been processed in a manufacturing process requiring or generating heat, for example in a milled form; for example in heat-dried form, especially a fluid-bed dried form or a spray dried form; for example in a form having been hot melt processed; for example in a form having been heat-sterilised by such as autoclaving.

A suitable solvate is a hydrate.

The invention also provides a process for preparing the Meso-Tartrate or a solvate thereof, characterised in that 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (Compound (I)) or a salt thereof, preferably dispersed or dissolved in a suitable solvent, is reacted with a source of meso-

tartrate ion and thereafter, if required, a solvate of the resulting Meso-Tartrate is prepared; and the Meso-Tartrate or a solvate thereof is recovered.

A suitable reaction solvent is a ketone for example acetone, or an ether for example tetrahydrofuran, an alkanol, such as propan-2-ol, a hydrocarbon, such as toluene, an ester, such as ethyl acetate, a nitrile such as acetonitrile, or a halogenated hydrocarbon such as dichloromethane or water, or an organic acid such as acetic acid; or a mixture thereof.

Conveniently, the source of meso-tartrate ion is meso-tartaric acid. The meso-tartaric acid is preferably added as a solid or in solution, for example in water or a lower alcohol such as methanol, ethanol, or propan-2-ol, or a mixture of solvents. An alternative source of meso-tartrate ion is provided by a suitably soluble base salt of meso-tartaric acid for example ammonium meso-tartrate, or the meso-tartaric acid salt of an amine, for example ethylamine or diethylamine.

The concentration of Compound (I) is preferably in the range 2 to 25% weight/volume, more preferably in the range 5 to 20%. The concentration of the tartaric acid solutions are preferably in the range of 5 to 125% weight/volume.

The reaction is usually carried out at ambient temperature or at an elevated temperature, for example at the reflux temperature of the solvent, although any convenient temperature that provides the required product may be employed.

Solvates, such as hydrates, of the Meso-Tartrate are prepared according to conventional procedures.

Recovery of the required compound generally comprises crystallisation from an appropriate solvent or mixture of solvents, conveniently the reaction solvent, usually assisted by cooling. For example, the Meso-Tartrate may be crystallised from a ketone such as acetone, or an ether such as tetrahydrofuran or water or a mixture thereof. An improved yield of the salt may be obtained by evaporation of some or all of the solvent or by crystallisation at elevated temperature followed by controlled cooling, optionally in stages. Careful control of precipitation temperature may be used to improve the reproducibility of the product form.

Crystallisation can also be initiated by seeding with crystals of the Meso-Tartrate or a solvate thereof but this is not essential.

When the mono tartrate salt comprise another monovalent salting ion such as an alkali metal or ammonium cation, the said ion is conveniently formed by reacting the mono tartrate salt with a solution of the chosen monovalent salting ion for example a metal or ammonium ion. Alternatively Compound (I) may be treated with a mono tartrate salt of the said monovalent salting ion.

Compound (I) is prepared according to known procedures, such as those disclosed in EP 0,306,228 and WO94/05659. The disclosures of EP 0,306,228 and WO94/05659 are incorporated herein by reference.

Meso-tartaric acid is a commercially available compound.

When used herein the term "T_{onset}" is generally determined by Differential Scanning Calorimetry and has a meaning generally understood in the art, as for example expressed in "Pharmaceutical Thermal Analysis, Techniques and Applications", Ford and Timmins, 1989 as "The temperature corresponding to the intersection of the pre-transition baseline with the extrapolated leading edge of the transition".

When used herein in respect of certain compounds the term "good flow properties" is suitably characterised by the said compound having a Hausner ratio of less than or equal to 1.5, especially of less than or equal to 1.25.

"Hausner ratio" is an art accepted term.

When used herein the term 'prophylaxis of conditions associated with diabetes mellitus' includes the treatment of conditions such as insulin resistance, impaired glucose tolerance, hyperinsulinaemia and gestational diabetes.

Diabetes mellitus preferably means Type II diabetes mellitus.

Conditions associated with diabetes include hyperglycaemia and insulin resistance and obesity. Further conditions associated with diabetes include hypertension, cardiovascular disease, especially atherosclerosis, certain eating disorders, in particular the regulation of appetite and food intake in subjects suffering from disorders associated with under-eating, such as anorexia nervosa, and disorders associated with over-eating, such as obesity and anorexia bulimia. Additional conditions associated with diabetes include polycystic ovarian syndrome and steroid induced insulin resistance.

The complications of conditions associated with diabetes mellitus encompassed herein includes renal disease, especially renal disease associated with the development of Type II diabetes including diabetic nephropathy, glomerulonephritis, glomerular sclerosis, nephrotic syndrome, hypertensive nephrosclerosis and end stage renal disease.

As mentioned above the compound of the invention has useful therapeutic properties: The present invention accordingly provides the Meso-Tartrate or a solvate thereof for use as an active therapeutic substance.

More particularly, the present invention provides the Meso-Tartrate or a solvate thereof for use in the treatment and/or prophylaxis of diabetes mellitus, conditions associated with diabetes mellitus and certain complications thereof.

The Meso-Tartrate or a solvate thereof may be administered per se or, preferably, as a pharmaceutical composition also comprising a pharmaceutically acceptable carrier.

Suitable methods for formulating the Meso-Tartrate or a solvate thereof are generally those disclosed for Compound (I) in the above mentioned publications.

Accordingly, the present invention also provides a pharmaceutical composition comprising the Meso-Tartrate or a solvate thereof and a pharmaceutically acceptable carrier therefor.

The Meso-Tartrate or a solvate thereof is normally administered in unit dosage form.

The active compound may be administered by any suitable route but usually by the oral or parenteral routes. For such use, the compound will normally be employed in the form of a pharmaceutical composition in association with a pharmaceutical carrier, diluent and/or excipient, although the exact form of the composition will naturally depend on the mode of administration.

Compositions are prepared by admixture and are suitably adapted for oral, parenteral or topical administration, and as such may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, pastilles, reconstitutable powders, injectable and infusable solutions or suspensions, suppositories and transdermal devices. Orally administrable compositions are preferred, in particular shaped oral compositions, since they are more convenient for general use.

Tablets and capsules for oral administration are usually presented in a unit dose, and contain conventional excipients such as binding agents, fillers, diluents, tableting agents, lubricants, disintegrants, colourants, flavourings, and wetting agents. The tablets may be coated according to well known methods in the art.

Suitable fillers for use include cellulose, mannitol, lactose and other similar agents. Suitable disintegrants include starch, polyvinylpyrrolidone and starch derivatives such as sodium starch glycolate. Suitable lubricants include, for example, magnesium stearate. Suitable pharmaceutically acceptable wetting agents include sodium lauryl sulphate.

Solid oral compositions may be prepared by conventional methods of blending, filling, tableting or the like. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers. Such operations are, of course, conventional in the art.

Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example

lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example, almond oil, fractionated coconut oil, oily esters such as esters of glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid, and if desired conventional flavouring or colouring agents.

For parenteral administration, fluid unit dose forms are prepared containing a compound of the present invention and a sterile vehicle. The compound, depending on the vehicle and the concentration, can be either suspended or dissolved. Parenteral solutions are normally prepared by dissolving the active compound in a vehicle and filter sterilising before filling into a suitable vial or ampoule and sealing. Advantageously, adjuvants such as a local anaesthetic, preservatives and buffering agents are also dissolved in the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum.

Parenteral suspensions are prepared in substantially the same manner except that the active compound is suspended in the vehicle instead of being dissolved and sterilised by exposure to ethylene oxide before suspending in the sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the active compound.

As is common practice, the compositions will usually be accompanied by written or printed directions for use in the medical treatment concerned.

As used herein the term 'pharmaceutically acceptable' embraces compounds, compositions and ingredients for both human and veterinary use: for example the term 'pharmaceutically acceptable salt' embraces a veterinarily acceptable salt.

The present invention further provides a method for the treatment and/or prophylaxis of diabetes mellitus, conditions associated with diabetes mellitus and certain complications thereof, in a human or non-human mammal which comprises administering an effective, non-toxic, amount of Meso-Tartrate or a solvate thereof to a human or non-human mammal in need thereof.

Conveniently, the active ingredient may be administered as a pharmaceutical composition hereinbefore defined, and this forms a particular aspect of the present invention.

In a further aspect the present invention provides the use of Meso-Tartrate or a solvate thereof for the manufacture of a medicament for the treatment and/or prophylaxis of diabetes mellitus, conditions associated with diabetes mellitus and certain complications thereof.

In the treatment and/or prophylaxis of diabetes mellitus, conditions associated with diabetes mellitus and certain complications thereof the Meso-Tartrate or a solvate

thereof may be taken in amounts so as to provide Compound (I) in suitable doses, such as those disclosed in EP 0,306,228, WO94/05659 or WO98/55122.

No adverse toxicological effects are indicated in the above mentioned treatments for the compounds of the invention.

The following examples illustrate the invention but do not limit it in any way.

Example 1 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione meso-tartrate

A mixture of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (8.0 g) and tetrahydrofuran (160 ml) was stirred and heated to 50°C. A solution of *meso*-tartaric acid (3.84 g) in water (20 ml) was added and the mixture stirred at 50°C for 15 minutes, filtered and the clear filtrate cooled to 21°C. The solvent was evaporated under reduced pressure at 40°C, acetone (40 ml) was added and the mixture stirred at 21°C to give a white suspension. The product was collected by filtration, washed with acetone and dried under vacuum to give 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione meso-tartrate (10.6 g) as a white, crystalline solid.

Example 2 5-[4-[2-(N-Methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione meso-tartrate

A mixture of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (3.0 g, 8.4 mmol), acetone (40 ml) and tetrahydrofuran (5 ml) was heated at reflux for 2.5 hours with stirring. To this was added a solution of *meso*-tartaric acid monohydrate (1.41 g, 8.4 mmol) in water (2 ml). The reaction mixture was heated at reflux with stirring for 2.5 hours, then cooled to 21°C and stirred for 16 hours at 21°C. The white solid was collected by filtration, washed with acetone (40 ml) then dried under reduced pressure for 2.5 hours at 21°C to afford 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione meso-tartrate (3.25 g) as a white crystalline solid.

Example 3 5-[4-[2-(N-Methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione meso-Tartrate

A mixture of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (10.0 g, 28 mmol), acetone (120 ml) and tetrahydrofuran (15 ml) was heated at reflux for 50 minutes with stirring. To this was added a solution of *meso*-tartaric acid monohydrate (4.7 g, 28 mmol) in water (6.0 ml). The reaction mixture was heated at reflux with stirring for 1 hour, then cooled to 21°C and stirred for 16 hours at 21°C. The white solid was collected by filtration, washed with acetone (50 ml) then dried under reduced pressure for 3 hours at 21°C to afford 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione meso-tartrate (11.7 g) as a white crystalline solid.

Characterising data recorded for the product of Example 1

The infrared absorption spectrum of a mineral oil dispersion of the product was obtained using a Nicolet 710 FT-IR spectrometer at 2 cm⁻¹ resolution (Figure 1). Data were digitised at 1 cm⁻¹ intervals. Bands were observed at: 3405, 1738, 1694, 1629, 1556, 1537, 1505, 1459, 1436, 1418, 1330, 1268, 1249, 1223, 1182, 1167, 1143, 1104, 1074, 1057, 1033, 1000, 949, 916, 887, 853, 818, 771, 717, 668, 619, 568, 528, 515 cm⁻¹.

The infrared spectrum of the solid product was recorded using Perkin-Elmer Spectrum One FT-IR spectrometer fitted with a universal ATR accessory. Bands were observed at: 3407, 2937, 2750, 1739, 1693, 1628, 1555, 1535, 1504, 1476, 1459, 1412, 1388, 1358, 1330, 1261, 1248, 1222, 1182, 1167, 1143, 1101, 1074, 1056, 1033, 999, 948, 916, 887, 853, 818, 771, 744, 717, 667 cm⁻¹.

The Raman spectrum of the product (Figure 2) was recorded with the sample in an NMR tube using a Nicolet 960 E.S.P. FT-Raman spectrometer, at 4 cm⁻¹ resolution with excitation from a Nd:V04 laser (1064 nm) with a power output of 400mW. Bands were observed at: 3101, 3059, 2952, 2922, 2877, 1739, 1604, 1544, 1458, 1438, 1394, 1331, 1270, 1222, 1203, 979, 887, 827, 739, 668, 638, 605, 472, 344 cm⁻¹.

The X-Ray Powder Diffractogram pattern of the product (Figure 3) was recorded using the following acquisition conditions: Tube anode: Cu, Generator tension: 40 kV, Generator current: 40 mA, Start angle: 2.0 °2θ, End angle: 35.0 °2θ, Step size: 0.02 °2θ, Time per step: 2.5 seconds. Characteristic XRPD angles and relative intensities are recorded in Table 1.

Table 1.

Angle	Rel. Intensity
2-Theta °	%
4.9	11.4
9.3	12.4
9.9	3.1
12.2	1.9
14.3	3.3
14.9	7
15.2	19
15.9	23.8
16.2	13.9
17.0	8.6
17.3	17.5
18.1	25.9
18.5	31.3
19.1	10.7
19.9	18.4

20.4	100
21.6	26
22.2	23.7
22.7	6.1
23.6	23.1
24.5	5.7
25.2	23
25.8	9.2
26.2	17.8
26.8	11.5
27.4	14.7
28.1	6.8
28.4	8.7
29.7	5.7
30.2	9.7
30.6	9.3
31.1	23.6
31.4	13.4
32.2	14
32.6	19.7
32.9	15.2
33.6	11.4
33.8	12.4
34.4	8.7
34.7	9

The solid-state NMR spectrum of the product (Figure 4) was recorded on a Bruker AMX360 instrument operating at 90.55 MHz: The solid was packed into a 4 mm zirconia MAS rotor fitted with a Kel-F cap and rotor spun at ca. 10 kHz. The ^{13}C MAS spectrum was acquired by cross-polarisation from Hartmann-Hahn matched protons (CP contact time 3ms, repetition time 15 s) and protons were decoupled during acquisition using a two-pulse phase modulated (TPPM) composite sequence. Chemical shifts were externally referenced to the carboxylate signal of glycine at 176.4 ppm relative to TMS and were observed at: 183.0, 177.2, 175.4, 173.0, 160.0, 159.0, 151.8, 144.2, 138.9, 134.3, 130.8, 128.2, 123.6, 113.7, 112.8, 77.4, 76.7, 74.5, 55.5, 53.5, 50.0, 42.4, 36.6, 33.8 ppm.

Properties of the Meso-Tartrate

Solid State Stability of the Meso-Tartrate, recorded for the product of Example 1

The solid state stability of the drug substance was determined by storing approximately 1.0 g of the material in a glass bottle at i) 40°C / 75% Relative Humidity (RH), open

exposure, for 1 month and b) at 50°C, closed, for 1 month. The material was assayed by HPLC for final content and degradation products in both cases.

a) 40°C / 75% RH: No significant degradation observed (HPLC assay 97% initial).

b) 50°C: No significant degradation observed (HPLC assay 98% initial).

Melting Point of the Meso-Tartrate

The melting point of the Meso-Tartrate was determined according to the method described in the U.S. Pharmacopoeia, USP 23, 1995, <741> "Melting range or temperature, Procedure for Class Ia", using a Buchi 545 melting point instrument.

Product of example 1, Melting Point: 149°C

Product of example 2, Melting Point: 153°C

Product of example 3, Melting Point: 155°C

T_{onset} of the Meso-Tartrate

The T_{onset} of the drug substance was determined by Differential Scanning Calorimetry using a Perkin-Elmer DSC apparatus.

Product of example 1, T_{onset} (10°C/minute, closed pan): 146°C

Product of example 2, T_{onset} (10°C/minute, open pan): 153°C


Product of example 3, T_{onset} (10°C/minute, open pan): 154°C

CLAIMS:

1. A compound 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, Meso-Tartrate salt or a solvate thereof.
2. A compound according to claim 1, characterised in that it provides:
 - (i) an infrared spectrum substantially in accordance with Figure 1;
 - (ii) a Raman spectrum substantially in accordance with Figure 2;
 - (iii) an X-Ray powder diffraction pattern (XRPD) substantially in accordance with Table 1 or Figure 3; or
 - (iv) a Solid State ^{13}C NMR spectrum substantially in accordance with Figure 4.
3. A compound according to claim 1, characterised in that it provides two or more of:
 - (i) an infrared spectrum substantially in accordance with Figure 1; and
 - (ii) a Raman spectrum substantially in accordance with Figure 2; and
 - (iii) an X-Ray powder diffraction pattern (XRPD) substantially in accordance with Table 1 or Figure 3; and
 - (iv) a Solid State ^{13}C NMR spectrum substantially in accordance with Figure 4.
4. A compound according to any one of claims 1 to 3, in purified form.
5. A compound according to any one of claims 1 to 3, in a solid dosage form.
6. A compound according to any one of claims 1 to 3, in a form being capable of pharmaceutical processing in a manufacturing process that requires or generates heat, for example milling; for example heat-drying especially fluid-bed drying or a spray drying; for example hot melt processing; for example heat-sterilisation such as autoclaving.
7. A compound according to any one of claims 1 to 3, in a form having been processed in a manufacturing process requiring or generating heat, for example in a milled form; for example in heat-dried form, especially a fluid-bed dried form or a spray dried form; for example in a form having being hot melt processed; for example in a form having being heat-sterilised by such as autoclaving.

8. A compound according to any one of claims 1 to 3, in a pharmaceutically acceptable form having good flow properties.
9. A process for preparing the Meso-Tartrate or a solvate thereof, characterised in that 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (Compound (I)) or a salt thereof, is reacted with a source of meso- tartarate ion and thereafter, if required, a solvate of the resulting Meso-Tartrate is prepared; and the Meso-Tartrate or a solvate thereof is recovered.
10. A pharmaceutical composition comprising 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione meso- tartrate or a solvate thereof and a pharmaceutically acceptable carrier therefor.
11. A compound 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione meso- tartrate or a solvate thereof, for use as an active therapeutic substance.
12. A use of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione meso- tartrate or a solvate thereof, for the manufacture of a medicament for the treatment and/or prophylaxis of diabetes mellitus, conditions associated with diabetes mellitus and certain complications thereof.

1/4

Fig. 1 Infrared spectrum of the Meso-Tartrate

2/4




Fig. 2 Raman spectrum of the Meso-Tartrate

Fig. 3 X-Ray Powder Diffractogram of the Meso-Tartrate

4/4

Fig. 4 Solid State ^{13}C NMR Spectrum of the Meso-Tartrate

Rosiglitazone meso-tartrate OA05677 MM48800-06681



INTERNATIONAL SEARCH REPORT

Int. Application No.

PCT/GB 01/03514

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D417/12 A61K31/44 A61P3/08

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, WPI Data, BEILSTEIN Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 94 05659 A (SMITHKLINE BEECHAM PLC ;POOL COLIN RIPLEY (GB); ROMAN ROBIN SHERWO) 17 March 1994 (1994-03-17) cited in the application page 2, line 14	1-12



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

Z document member of the same patent family

Date of the actual completion of the international search

26 September 2001

Date of mailing of the international search report

05/10/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Steendijk, M

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 01/03514

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9405659	A	17-03-1994	AP 513 A 30-07-1996
			AT 182147 T 15-07-1999
			AU 674880 B2 16-01-1997
			AU 4973093 A 29-03-1994
			BR 1100916 A3 04-07-2000
			CA 2143849 A1 17-03-1994
			CN 1101911 A ,B 26-04-1995
			CN 1183275 A ,B 03-06-1998
			CN 1183413 A ,B 03-06-1998
			CN 1183276 A ,B 03-06-1998
			CZ 9500565 A3 15-11-1995
			DE 69325658 D1 19-08-1999
			DE 69325658 T2 30-12-1999
			DK 658161 T3 29-11-1999
			EP 0658161 A1 21-06-1995
			EP 0960883 A1 01-12-1999
			ES 2133410 T3 16-09-1999
			FI 951004 A 03-03-1995
			FI 982413 A 06-11-1998
			WO 9405659 A1 17-03-1994
			GR 3030794 T3 30-11-1999
			HK 1012363 A1 05-05-2000
			HU 72639 A2 28-05-1996
			IL 106904 A 30-09-1997
			JP 11147885 A 02-06-1999
			JP 2828777 B2 25-11-1998
			JP 8501095 T 06-02-1996
			LU 90712 A9 12-03-2001
			MX 9305397 A1 31-01-1995
			NO 950852 A 03-03-1995
			NO 974646 A 03-03-1995
			NZ 255505 A 22-08-1997
			PL 307812 A1 26-06-1995
			RU 2128179 C1 27-03-1999
			SG 48302 A1 17-04-1998
			SI 9300452 A 30-06-1994
			SK 27795 A3 09-08-1995
			TW 385309 B 21-03-2000
			US 5741803 A 21-04-1998
			US 5910592 A 08-06-1999
			ZA 9306509 A 16-06-1994